These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. [Preclinical AD and Biomarker; from J-ADNI to AMED Preclinical Study]. Suzuki K Brain Nerve; 2017 Jul; 69(7):691-700. PubMed ID: 28739982 [TBL] [Abstract][Full Text] [Related]
11. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia]. Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ; Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080 [TBL] [Abstract][Full Text] [Related]
12. Preclinical AD predicts decline in memory and executive functions in subjective complaints. van Harten AC; Smits LL; Teunissen CE; Visser PJ; Koene T; Blankenstein MA; Scheltens P; van der Flier WM Neurology; 2013 Oct; 81(16):1409-16. PubMed ID: 24049134 [TBL] [Abstract][Full Text] [Related]
13. Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project. Ritchie K; Ropacki M; Albala B; Harrison J; Kaye J; Kramer J; Randolph C; Ritchie CW Alzheimers Dement; 2017 Feb; 13(2):186-195. PubMed ID: 27702619 [TBL] [Abstract][Full Text] [Related]
14. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773 [TBL] [Abstract][Full Text] [Related]
15. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL; Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471 [TBL] [Abstract][Full Text] [Related]
16. The evolution of preclinical Alzheimer's disease: implications for prevention trials. Sperling R; Mormino E; Johnson K Neuron; 2014 Nov; 84(3):608-22. PubMed ID: 25442939 [TBL] [Abstract][Full Text] [Related]
17. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease. Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737 [TBL] [Abstract][Full Text] [Related]
18. Subjective Cognitive Decline in Preclinical Alzheimer's Disease. Rabin LA; Smart CM; Amariglio RE Annu Rev Clin Psychol; 2017 May; 13():369-396. PubMed ID: 28482688 [TBL] [Abstract][Full Text] [Related]
19. Biomarkers, ketone bodies, and the prevention of Alzheimer's disease. VanItallie TB Metabolism; 2015 Mar; 64(3 Suppl 1):S51-7. PubMed ID: 25468143 [TBL] [Abstract][Full Text] [Related]
20. The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis. Szalárdy L; Zádori D; Klivényi P; Vécsei L J Alzheimers Dis; 2016 May; 53(2):373-92. PubMed ID: 27163812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]